Skip to content

Manufacturer Direct D2C and the Future of Independent Pharmacy | TWIRx Special Series

Pharmacy Podcast Network

40m
Transcript

Original podcast

Where to listen

Summary

Written by a model from the transcript; not yet reviewed.

This podcast episode explores the structural shifts in the pharmacy landscape driven by manufacturer direct-to-consumer and direct-to-employer models, featuring insights from industry expert Shelley Bailey and retail pharmacy owner Sammy Salem. The discussion focuses on how these emerging programs, pioneered by organizations like IPC, bypass traditional Pharmacy Benefit Manager intermediaries to provide transparent pricing, lower out-of-pocket costs for patients, and favorable reimbursement margins for independent pharmacies. The guests explain how integrating manufacturer-supported programs into standard dispensary workflows can bridge financial gaps caused by aggressive PBM rates and changing 340B dynamics. Listeners will find value in the practical advice on navigating these disruptive supply chain changes, leveraging digital health networks, and positioning independent community pharmacies as healthcare hubs.

  • Independent pharmacies can participate in manufacturer direct programs without changing their standard dispensing workflows or adding operational strain. 16:51
  • Manufacturer-supported programs help capture underinsured or uninsured patients by providing transparent, affordable pricing directly at the point of sale. 9:41
  • Pharmacies interested in exploring direct-to-consumer manufacturer programs can begin by reaching out to the IPC Digital Health Team for guidance and onboarding. 33:20
  • Independent pharmacies must stay adaptable by combining traditional dispensing with ancillary offerings like clinical services, remote monitoring, and direct manufacturer partnerships. 35:35

Chapters

  1. 0:05
    Podcast Introduction and Host Overview

    The hosts introduce the Pharmacy Podcast Network and set the stage for the episode’s focus on pharmacy industry changes.

  2. 0:39
    Rise of Direct-to-Consumer Pharmacy Models

    The discussion highlights the shift toward manufacturers sourcing directly to consumers, citing examples like Lilly Direct and Pfizer Direct.

  3. 1:22
    Introducing Shelley Bailey and IPC Partnership

    The hosts welcome Shelley Bailey, who explains her role at IPC and the partnership with manufacturers.

  4. 2:24
    Shelley Explains D2C Foundations

    Shelley outlines the historical context of pharmacy payment models and the emergence of D2C and D2E programs.

  5. 4:03
    Impact of D2C on Independent Pharmacies

    Shelley and the hosts discuss how D2C programs affect pharmacy revenue, patient access, and relationships with manufacturers.

  6. 9:32
    Win‑Loss Analysis of Manufacturer‑Supported Programs

    The panel debates whether manufacturer‑direct programs create a win‑win or a loss‑win for pharmacies, patients, and manufacturers.

  7. 15:18
    Payment Mechanics and Workflow Integration

    The conversation explains how pharmacies are paid within D2C programs, emphasizing standard workflow and reimbursement timelines.

  8. 20:24
    Future Trends: Cost‑Plus and Direct‑Employer Models

    Speakers predict a shift toward cost‑plus pharmacies and direct‑employer partnerships, reshaping drug benefit structures.

  9. 30:45
    Expanding Pharmacy Services Beyond Dispensing

    The hosts explore how independent pharmacies can grow through immunizations, remote monitoring, and other ancillary services.

  10. 32:38
    Call to Action: Engage with IPC and AAPA

    Listeners are encouraged to reach out to IPC, AAPA, and manufacturers to join D2C programs and enhance pharmacy operations.

  11. 39:40
    Episode Closing and Future Events

    The hosts wrap up, thank guests, and preview upcoming events and sponsorships.

Highlights

  • 3:22

    Explosion of Direct to Consumerinsight

    Shelley Bailey explains how traditional retail pharmacies were left out of the recent explosion of direct-to-consumer and direct-to-employer programs launched by manufacturers like Pfizer and Lilly.

  • 6:01

    Prescriptions Leaving Retail Countersstory

    Sammy Salem shares that retail pharmacies were historically carved out of these programs, leading to lost prescriptions when patients were directed to manufacturer websites instead.

  • 9:58

    Transparent Point of Sale Pricinginsight

    The guests argue that manufacturer direct programs remove hidden backend clawbacks like DIR fees, offering a transparent model where the patient cost and pharmacy rebate are clear.

  • 19:37

    Favorable Reimbursement Ratesdata

    Shelley Bailey notes that reimbursement rates through these manufacturer-direct partnerships are more favorable for pharmacies than anything seen in the market in over a decade.

  • 28:01

    Shifting 340B Contract Modelsinsight

    Shelley Bailey predicts that 340B contract pharmacy models will undergo significant changes and reductions in claims over the next two to three years due to evolving rebate structures.

  • 33:20

    Actionable Steps for Pharmaciesstrategy

    Shelley Bailey provides a specific starting strategy for independent pharmacy owners wanting to access these innovative models by contacting the IPC Digital Health Team.

Quotes

  • “Our manufacturers are now direct sourcing and direct to consumer, which is known as D to C pharmacy models.”
    Unnamed speaker · 0:48
  • “I mean, ultimately, we're here for the patient. We're a patient centered approach, no matter what we do.”
    Unnamed speaker · 10:34
  • “There is no magic pot of gold. It's just more of that money is coming from the manufacturer direct to the pharmacy.”
    Unnamed speaker · 20:07
  • “I think there's a huge trend on all these sorts of off-benefit models. 2026 is going to probably be the biggest year of commercial coverage for programs like GLP-1s under the traditional funded benefit.”
    Unnamed speaker · 21:42
  • “The first thing is, this doesn't cost anything to any pharmacy to be a part of, you know, and that's the first thing that everyone says, what's a catch, right?”
    Unnamed speaker · 36:09
  • Independent Pharmacy Cooperative 39:40–39:50

About this episode

In this IPC-sponsored episode, Todd Eury explores how manufacturer-direct programs, direct-to-consumer channels, cash-pay models, specialty carve-outs, and new reimbursement structures are reshaping medication access and independent pharmacy. Joining the conversation are Shelley Bailey of Independent Pharmacy Cooperative and Sammy Salem, Principal Owner and COO of Vios Health and an Executive Board Member of AAPARx. Manufacturer-direct care is often associated with websites, telehealth, and mail-order fulfillment—but it does not have to exclude community pharmacy. IPC is developing infrastructure that allows patients to receive manufacturer-supported pricing while participating independent pharmacies remain the dispensing location. The discussion examines IPC’s manufacturer-sponsored GLP-1 opportunities and a broader network covering more than 140 branded medications. Shelley and Sammy explain how these programs can improve patient affordability, create more sustainable pharmacy economics, and help independent pharmacies reconnect with patients lost to online and manufacturer-controlled channels. Topics include: Whether the traditional pharmacy benefit is beginning to fragment How manufacturer-direct programs can include independent pharmacy The economics behind manufacturer-supported reimbursement Finding patients facing denied authorizations, high deductibles, lost coverage, or limited brand access Why excellent service must now be paired with digital access and new payment models Employer drug carve-outs and the importance of evaluating total benefit economics Point-of-sale affordability and acquisition-cost protections What manufacturers need to provide for pharmacy participation How successful pharmacies can prepare for the next access model The central message is clear: the industry may not need to create new dollars—it needs to change where existing dollars land. In partnership with GoodRx, this manufacturer-direct program combines GoodRx’s trusted consumer platform and broad patient reach with IPC’s nationwide network of independent pharmacies. Together, we create a more direct and accessible path from patient engagement to prescription fulfillment—while keeping community pharmacies at the center of care. IPC GPO members interested in participating should contact their IPC Regional Director. Other IPC members, affiliates, and interested pharmacies can reach IPC Digital Health at [email protected]. Host: Todd S. Eury, Pharmacy Podcast NetworkGuests: Shelley Bailey, IPC; Sammy Salem, AAPARx and Vios HealthSponsored by: Independent Pharmacy Cooperative

Transcript

0:00
40:34

7,078 words · 4 speakers

Topics

  • IPC
  • 340B
  • AAPA
  • PBM
  • Michigan
  • D to E
  • PSAO
  • West Virginia
  • Pfizer Direct
  • Lilly Direct

Page updated · transcript and summary are machine-generated